Tougeron David

10 Must-Read Posts in GI Oncology This Week | Fourth Week of July This week’s selection covers: • ctDNA in biliary tract cancers and cholangiocarcinoma recurrence • Practice heterogeneity in non-metastatic pancreatic adenocarcinoma • Liver resection vs multibipolar RFA in early HCC • Proteomic secretome dataset in pancreatic cancer • Daraxonrasib pancreatic cancer data in NEJM • Explainable synergy predictions for CRC drug combinations • Neoadjuvant immunotherapy vs non-operative management in dMMR/MSI gastroesophageal adenocarcinoma • Daraxonrasib accelerated FDA review in metastatic PDAC • PET/MR imaging of the GI tract • IMMUNODIG in dMMR/MSI-H digestive tumors @david_tougeron @kkbhinder @Erman_Akkus @asmundflobak @NelsonDusetti @NaultJc @DelayeMatthieu @MaenAbdelrahim Read more on OncoDaily - oncodaily.com/oncolibrary/ga… #GIOncology #OncoDaily

🔟 Must-Read in GI Oncology | Apr 27–May 3 A week of momentum across early-phase innovation, translational science, and real-world evidence👇 🔬 Highlights: • COMPANION-002: PFS + ORR improvement in BTC • MONTBLANC: Phase II HCC fully enrolled • COLOSOTO: Fast enrollment (KRAS G12C mCRC) • mFOLFOXIRI → CRT: ORR 30.8%, pCR 20.5% (LARC) • CEA-directed T cell engager + 4-1BB: MSS CRC strategy • Nano-273: overcoming IO resistance (preclinical) • Anal cancer cohort: CRT outcomes • CME meta-analysis: survival benefit • FDA early access: pancreatic cancer • Risk models: earlier detection 💡 Takeaway: Progress is driven by early-phase + translational + real-world convergence. @VivekSubbiah @RashidLui @staclinds @DuxinSun @N_BenKhaled @JuliaMayerle @EnricoNDeToni @forghy @JMarescauxIrcad @ElieRassy @StefanMichiels @TPudlarz @david_tougeron 📎oncodaily.com/oncolibrary/10… #GIOncology #Oncology #CancerResearch #Immunotherapy #CRC #PancreaticCancer #HCC #BTC #ClinicalTrials #OncoDaily